These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31119266)

  • 41. Flaws in Anticoagulation Strategies in Patients With Atrial Fibrillation at Hospital Discharge.
    Kartas A; Samaras A; Vasdeki D; Dividis G; Fotos G; Paschou E; Forozidou E; Tsoukra P; Kotsi E; Goulas I; Efthimiadis G; Karvounis H; Tzikas A; Giannakoulas G
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):225-232. PubMed ID: 30599759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Corrigendum to: Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke and Low quality of some generic cardiovascular medicinal products represents a matter for growing concern.
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):309. PubMed ID: 32932522
    [No Abstract]   [Full Text] [Related]  

  • 43. Validation of CHA2DS2 VASc Score Predictability of Stroke and Systemic Embolization in a Middle Eastern Population with AF: The Jordan Atrial Fibrillation (JoFib) Study.
    Ibdah R; Obeidat O; Khader Y; Al-Nusair J; Abusurrah O; Obeidat A; Obeidat A; Rawashdeh S; Alrabadi N; Obiedat AF; Alnadi NN; Hammoudeh A
    Vasc Health Risk Manag; 2023; 19():255-264. PubMed ID: 37125391
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study.
    Yoon M; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
    Thromb Haemost; 2018 Jul; 118(7):1296-1304. PubMed ID: 29723875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1.
    Sulzgruber P; Wassmann S; Semb AG; Doehner W; Widimsky P; Gremmel T; Kaski JC; Savarese G; Rosano GMC; Borghi C; Kjeldsen K; Torp-Pedersen C; Schmidt TA; Lewis BS; Drexel H; Tamargo J; Atar D; Agewall S; Niessner A
    Eur Heart J; 2019 Sep; 40(36):3010-3012. PubMed ID: 31541549
    [No Abstract]   [Full Text] [Related]  

  • 46. Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA2DS2-VASc Score of 1 (Men) or 2 (Women)?
    Hung Y; Chao TF; Liu CJ; Tuan TC; Lin YJ; Chang SL; Lo LW; Hu YF; Liao JN; Chung FP; Lin WY; Lin WS; Cheng SM; Chen TJ; Lip GY; Chen SA
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27702803
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. When to withhold oral anticoagulation in atrial fibrillation - an overview of frequent clinical discussion topics.
    Seelig J; Pisters R; Hemels ME; Huisman MV; Ten Cate H; Alings M
    Vasc Health Risk Manag; 2019; 15():399-408. PubMed ID: 31571891
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage.
    Chao TF; Liu CJ; Liao JN; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chen TJ; Lip GY; Chen SA
    Circulation; 2016 Apr; 133(16):1540-7. PubMed ID: 26969761
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atrial fibrillation in New Zealand primary care: Prevalence, risk factors for stroke and the management of thromboembolic risk.
    Tomlin AM; Lloyd HS; Tilyard MW
    Eur J Prev Cardiol; 2017 Feb; 24(3):311-319. PubMed ID: 27798365
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CHA
    D'Souza M; Carlson N; Fosbøl E; Lamberts M; Smedegaard L; Nielsen D; Torp-Pedersen C; Gislason G; Schou M
    Eur J Prev Cardiol; 2018 Apr; 25(6):651-658. PubMed ID: 29482441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CHA
    Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
    Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Geriatric Conditions Are Associated With Decreased Anticoagulation Use in Long-Term Care Residents With Atrial Fibrillation.
    Zhang N; Patel J; Chen Z; Zhou Y; Crawford S; McManus DD; Gurwitz J; Shireman TI; Kapoor A
    J Am Heart Assoc; 2021 Aug; 10(16):e021293. PubMed ID: 34387127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevalence and predictors of inappropriate anticoagulation in patients with a CHA
    Saberian S; Badin A; Siebert V; Roy A; Banga S; Ghadiam HR; Wigant RR; Aggarwal A; Baman TS
    Int J Cardiol; 2017 Dec; 248():179-181. PubMed ID: 28807511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
    Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
    Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis.
    van Doorn S; Debray TPA; Kaasenbrood F; Hoes AW; Rutten FH; Moons KGM; Geersing GJ
    J Thromb Haemost; 2017 Jun; 15(6):1065-1077. PubMed ID: 28375552
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project.
    Fauchier L; Lecoq C; Clementy N; Bernard A; Angoulvant D; Ivanes F; Babuty D; Lip GY
    Chest; 2016 Apr; 149(4):960-8. PubMed ID: 26425935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Miyamoto K; Aiba T; Arihiro S; Watanabe M; Kokubo Y; Ishibashi K; Hirose S; Wada M; Nakajima I; Okamura H; Noda T; Nagatsuka K; Noguchi T; Anzai T; Yasuda S; Ogawa H; Kamakura S; Shimizu W; Miyamoto Y; Toyoda K; Kusano K
    Heart Vessels; 2016 Aug; 31(8):1327-36. PubMed ID: 26276272
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.